risk-of-Cardiovascular-Disease

A recently published follow-up research article has reported that the blood pressure-lowering drugs, statins and antihypertensives do not decrease the risk of Cardiovascular Disease among patients with an intermediate risk

 

A recently-conducted randomized trial called the Heart Outcomes Prevention Evaluation -3 trial (HOPE-3) had claimed that the usage of two types of blood pressure lowering drugs, statins (cholesterol-lowering drugs) and antihypertensives (blood pressure-reducing drugs), decreases the risk of Cardiovascular Disease in adult patients categorized as having an intermediate risk. Contrarily, a new follow-up research article published in the British Medical Journal reports that statins and antihypertensives do not, in fact, reduce the risk of Cardiovascular Disease in patients with an intermediate risk.

To explore the effects of both types of drugs, researchers used a randomized controlled trial design and assigned participants into 2 groups: one group to receive a placebo and the other group to receive the active treatment (blood pressure-lowering drugs) over the course of several years.

During the study, 260 (4.1%) of patients within the active treatment group died from Cardiovascular Disease or suffered a non-fatal heart attack or stroke in comparison to 279 (4.4%) patients in the placebo group.

Researchers of this study concluded that the decrease in the mean blood pressure was only insignificantly greater within the active treatment group versus the placebo group (6.0/3.0mm Hg). Moreover, the authors add that neither of the drugs used in the trial have ever been demonstrated to lower the risk of Cardiovascular Disease at such low doses. They also add that these study results do not mean that there is no possibility that a portion of this low-risk population could benefit from longer treatment with blood pressure-lowering drugs.

 

Are you at risk of Cardiovascular Disease? Find out your risk level here:

https://www.cvdriskchecksecure.com/framinghamriskscore.aspx

 

 

 

Written By: Melissa Booker

Facebook Comments